Teva Pharmaceuticals (NASDAQ: TEVA) posted earnings at $0.69 EPS on revenues of $2.58 Billion; First Call had consensus at $0.66 EPS on $2.48 Billion in revenues.
There are some big numbers ahead for Teva if it sees approvals on its generics: Teva had 160 applications awaiting final FDA approval, and the brand names for the generic drugs had annual U.S. sales of some $101 Billion; it also noted that it was first-to-file on what would be some $40 Billion in annual U.S. brand drug sales.
Gross profit margin reached 52.3 percent in Q4-2007. As of December 31, 2007, Teva’s cash and equivalents were listed as $3.3 billion and shareholders equity reached $13.7 billion. Teva also raised its dividend by about 12% to roughly $0.124 after currency conversions.
Its total shares outstanding were listed as 834 million shares, and it sees some 837 million shares being the "going forward" share count.
Jon C. Ogg
February 12, 2008
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.
Latest from 24/7
